
CURRICULUM VITAE

Arta Monir Monjazez, M.D., Ph.D.

Personal Information

Work Address: 4501 X Street, Ste 0148
Sacramento, CA 95817
Phone: (916) 734-8252
Fax: (916) 703-5069
Cell Phone: (336) 575 2977
Email: ammonjazez@ucdavis.edu
Web Site: <http://www.ucdmc.ucdavis.edu/radonc/>
Date of Birth: 10/30/1975
U.S Citizen: Yes

Education

Education and Training

1993-1997	University of California at Berkeley, Berkeley, CA B.A., Molecular and Cell Biology, with Honors in Immunology (May 1997)
1998-2003	Wake Forest University School of Medicine, Graduate School of Arts and Sciences, Winston-Salem, NC PhD, Doctor of Philosophy in Cancer Biology (May 2003)
1998-2005	Wake Forest University School of Medicine, Winston-Salem, NC, M.D., Doctor of Medicine, class rank 6/110
2005-2006	Harbor – UCLA Medical Center, Torrance, CA, Intern, Transitional Year Medicine (Darrell W. Harrington, M.D., Program Director)
2006-2010	Wake Forest University Baptist Medical Center, Winston-Salem, NC, Resident, Department of Radiation Oncology (Kevin P. McMullen, M.D., Program Director)
2009-2010	Wake Forest University Baptist Medical Center, Winston-Salem, NC, Chief Resident, Department of Radiation Oncology (Kevin P. McMullen, M.D., Program Director)

Personal Statement

I am a Professor of Radiation Oncology and a clinician scientist leading the clinical care of patients, a high-powered basic science research enterprise, and cutting-edge human clinical trials. I have extensive experience leading teams of diverse individuals from varying disciplines in activities including clinical trials, basic science research, clinical care, education, and diversity / inclusion. I serve(d) in leadership roles in radiation oncology and cancer immunotherapy on an institutional and national level including leading a basic science research laboratory, heading GI and sarcoma radiotherapy at UC Davis, leading the immunotherapy efforts for the UC Davis Comprehensive Cancer Center, heading Radiobiology for the Department of Radiation Oncology at UC Davis, Immunotherapy Committee Co-Chair at NRG oncology, and PI of institutional

investigator initiated trials and national clinical trials through ETCTN and SWOG / NRG. Throughout my career I have demonstrated the ability to build and lead highly successful teams and have been awarded the prestigious Dean's Award for Excellence in Team Science. I have the strength to maintain vision and direction, the humility to accept criticism and adjust when needed, and the experience required to understand that successful leadership empowers others.

In the clinic I specialize in the treatment of gastrointestinal malignancies and sarcomas. I hold national leadership positions and have published extensively on the management of these diseases. My research has two major themes. The first focuses on understanding mechanisms of resistance to cancer immunotherapy and exploring combinatorial strategies, including combined radiotherapy and immunotherapy, to overcome resistance. The second is understanding how aging and obesity affects inflammation and immunity in the context of cancer development, progression, and therapy. My research is truly translational in nature spanning from basic mechanistic studies to murine models to large animal companion canine clinical trials and human clinical trials. I am uniquely trained for this line of research with an honors thesis in immunology at the University of California, Berkeley, a PhD in Cancer Biology and Inflammation, a Holman pathway research fellowship in cancer immunology, board certification as a radiation oncologist, and training through the UC Davis K12 program in translational cancer immunotherapy.

Employment

Employment History

09/2010-08/2015	UC Davis Comprehensive Cancer Center, Sacramento, CA Department of Radiation Oncology Laboratory of Cancer Immunology Assistant Professor
08/2015 – 06/2021	UC Davis Comprehensive Cancer Center, Sacramento, CA Department of Radiation Oncology Laboratory of Cancer Immunology Associate Professor
01/2016 – 07/2021	UC Davis Comprehensive Cancer Center, Sacramento, CA CCSG Staff Investigator – Immunotherapy
07/2021 – Present	UC Davis Comprehensive Cancer Center, Sacramento, CA Department of Radiation Oncology Laboratory of Cancer Immunology Professor
07/2021 - Present	UC Davis Comprehensive Cancer Center, Sacramento, CA Director Cancer Immunology and Energetics Program
04/2024 - Present	UC Davis Comprehensive Cancer Center, Sacramento, CA

Department of Radiation Oncology
Laboratory of Cancer Immunology
Professor and Director of Radiation Biology

Board Certifications

May 2011 Board Certification in Radiation Oncology by American Board of Radiology

Honors & Awards

1997	Honors Thesis in Immunology, University of California, Berkeley
1998 - 2005	MD/PhD Full Tuition Scholarship
Fall 2004	Alpha Omega Alpha (AOA) Medical Honors Society
Spring 2005	Pritchard History of Medicine Award
Spring 2005	M. R. Cooper Scholarship for excellence in Oncology
Spring 2005	Clinical Honors in Radiation Oncology
Fall 2007	Howard H. Wong Scholarship in Radiation Oncology
2006 - 2010	B.L Holman Research Pathway Scholar in Radiation Oncology
2011 - 2012	American Cancer Society Institutional Research Grant -- Pilot Study of Combined Radiotherapy and Immunotherapy in Metastatic Canine Sarcomas
2011 - 2014	K12 Mentored Clinical/Translation Research Fellowship
2012 - 2013	Amador Cancer Research Foundation, Christine and Helen Landgraf Award
2013	NIH Association for Clinical and Translational Science – Outstanding Abstract Award
2014 - 2019	NCI NRG Oncology Committee on Immunotherapy and Immunomodulation
2015 - Present	NCI PD-L1 Development Project Team Member
2016 - Present	CTEP Clinical Trial Design and Immuno-oncology Agent Working Group
2016 - Present	Sacramento's Top Doctors – Sacramento Magazine
2017	Dean's Award for Excellence – Team Science, Canine Cancer Immunotherapy Team, University of California, Davis
2019 – 2022	Chairperson, NCI NRG Oncology Committee on Immunotherapy and Immunomodulation
2022	Oettinger Memorial Award for Outstanding Cancer Research

Grants / Clinical Trials / Contracts

Active

1 R01 CA 240751- 01 (PI: A.M. Monjazeb)

03/01/2022-2/28/2027

Role: PI

NIH/NCI

The Impact of Obesity on Radiotherapy Anti-Tumor Effects

Specific Aim(s): To understand the impact of obesity on radiotherapy sensitivity and the underlying mechanisms. To explore strategies to overcome obesity induced radio-resistance.

Total Award Amount (including Indirect Costs): \$3,220,419.00

3 R01 CA 240751 – 01S1

03/01/2022-2/28/2027

Role: PI

NIH/NCI

The Impact of Obesity on Radiotherapy Anti-Tumor Effects

Specific Aim(s): A diversity supplement award for the parent grant listed above for the support of graduate student Logan Vick who is from an under-represented minority group (African American) in the biological sciences.

Total Award Amount (including Indirect Costs): \$592,417.00

SWOG/NRG S1914

8/1/2019 – 7/31/2024

Role: Study Chair (Translational Medicine)

NIH/NCI

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC.

Specific Aim(s): This is an international phase III clinical trial testing the addition of checkpoint inhibition to SBRT for early stage NSCLC. This trial is based on our institutional phase 1 trial testing this same concept.

Total Award amount (including Indirect Costs): N/A

UCDCC272

8/1/2018 – 7/30/2025

Role:PI

Merck

Phase I/II trial of Intralesional IL-2 and Pembrolizumab in patients with primary or acquired resistance to PD-1/PD-L1 checkpoint inhibitors.

Specific Aim(s): This phase I/ II trial will determine the safety, preliminary efficacy, and changes in mechanistic immune biomarkers induced by this novel immunotherapy combination arising from my pre-clinical research.

Total Award amount (including Indirect Costs): \$954,966.00

UCDCC251/ML29551 (PI: A.M.Monjazebe, K.Kelly)

05/01/2015 – 05/30/2023

Role: Co-PI

Genentech

Pilot Study of MPDL3280A plus Stereotactic Ablative Radiotherapy (SAR) in Non-Small Cell Lung Cancer

Specific Aims(s): A phase 1 study testing various sequencing strategies of MPDL3280A + SAR in stage IV NSCLC examining safety, feasibility, radiographic response rates, and extensive correlative biomarkers.

Total Award amount (including Indirect Costs): \$821,656.00

Completed

NIH Training Grant

2000 – 2001

Role: Trainee

Research Grant

2001 – 2003

Role: Trainee, PI

United States Army Research Acquisition Activity Award

Departmental Research Grant Role: PI Wake Forest University Department of Radiation Oncology	2008 - 2009
Resident Research Grant Role: PI RSNA Mechanism of Anti-tumor Immunity Induced by Radiotherapy and Irradiated Autologous Tumor Vaccination	2009 – 2010
IRG-95-125-07 Role: PI American Cancer Society, Institutional Research Grant Specific Aim(s): A Pilot Study of Combined Radiotherapy and Immunotherapy in Metastatic Canine Sarcomas: determining immunologic markers of clinical response. 07/01/2010 – 06/31/2011	2011
Research Grant Role: PI Amador Cancer Research Foundation, Christine and Helen Landgraf Award	2012 – 2013
2 KL2 RRO24144-06 (PI: L. Berglund) Role: Project PI NIH/NCRR UC Davis Clinical and Translation Science Center K12 Mentored Research Fellowship Combined Radiotherapy and Immunotherapy with CpG oligodeoxynucleotides and blockade of indolamine 2,3 dioxygenase. Specific Aim(s): The major goal of this program is to train junior faculty scholars into independent researchers.	07/01/2011 – 06/30/2014
P30 CA093373 (PI: R. deVere White) Role: Project PI NIH/NCI VTX-2337 plus Radiotherapy for Metastatic Canine Malignancies Collaborative Institutional Research Grant Pilot Funding for Investigators in Oncology Specific Aim(s): This project is testing a novel TLR agonist immunotherapy in combination with hypofractionated radiotherapy for the treatment of metastatic canine melanomas and sarcomas.	01/01/2015 – 06/01/2016
V4TH612 (PI: M. Kent) Role: Co-I Oncosec Medical Specific Aims(s): Examining the anti-tumor and immunologic effects of cytokine plasmids in canine sarcomas.	01/01/2015 - 12/31/2017
R01 CA195904 (PI: W. Murphy) Role: Co-Investigator NIH/NCI Interdisciplinary Collaboration for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically and Metabolically relevant Models of Breast Cancer. Specific Aims(s): We propose to use aged and obese mouse models as well as large outbred canine cancer patients to demonstrate that inflammatory/immune related differences present in these models	05/15/2015 – 04/30/2018

serve as biomarkers important to the development of clinical toxicities, particularly those seen with immunotherapy and radiotherapy, that need to be accounted in human cancer patients that tend to be over the age of 65 with 2/3 of the US population being either overweight or obese. These studies will address the critical need for improvement of preclinical modeling, with migration away from the one-size-fits-all approach of utilizing young, lean subjects toward one more reflective of the actual disease state of the human cancer patient.

UCDCC269

7/1/2017- 6/30/2018

Role:PI

Philanthropic Support

A Pilot Clinical Trial of PD-1 Inhibition, Intravesicular IL-2, and Radiotherapy in NSCLC resistant to PD-1 blockade.

Specific Aim(s): A pilot trial testing the feasibility of this novel combination aimed at reversing resistance to PD-1 checkpoint blockade. This novel immunotherapy combination arising from my pre-clinical research.

NCI 10021

7/1/2017 – 6/30/2019

Role:Co-PI

ETCTN

A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC.

Specific Aim(s): This phase II trial will determine the safety, efficacy, and changes in mechanistic immune biomarkers induced by this novel immunotherapy combination. It will also examine the different immune modulatory effects of low vs. high dose radiotherapy.

UCDCC263 / TG4010.22 / CA209-527

12/15/2016-12/14/2019

Role: Co-PI

Transgene

Phase II Trial of TG4010 plus Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) who have Progressed after One Line of Systemic Therapy

Specific Aim(s): This phase II trial will determine the safety, preliminary efficacy, and changes in mechanistic immune biomarkers induced by vaccination in combination with checkpoint blockade.

P30CA093373-14S4 (PI: R. deVere White)

09/01/2016-08/31/2019

Role: Project PI

NIH/NCI

Cancer Center Support Grant P30: Genomic and Immunologic analysis of Canine High Grade Gliomas, Melanomas, and Osteosarcomas

Specific Aim(s): To determine the mutational load / neo-antigen burden, mutations in known cancer pathways, and tumor microenvironment immunophenotype of canine malignancies.

R01 CA189209 (PI: W. Murphy)

04/01/2015 – 03/31/2021

Role: Co-I

NIH/NCI

Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies

Specific Aim(s): This project seeks to assess the efficacy of combining immunotherapy using natural killer cells with radiation in targeting cancer stem cells from solid tumors using mouse and canine models.

NIH LRP (PI: A.M. Monjazeb)

07/01/2013 – 06/31/2021

Role: PI

NIH/NCI
Loan Repayment Program for Clinical Researchers

Immuno-Oncology Pilot Funding 9/1/2019 – 12/1/2022
Role: PI
UCDCCC

The Role of Tertiary Lymphoid Structures and B cells in Cancer Immunotherapy.
Specific Aims: To understand how the antigen presenting B cells in the tumor microenvironment influence antitumor immune responses and immunotherapy outcomes.

UCDCC258 / LC140178 (PI: K. Kelly) 06/01/2015-12/01/2022
Role: Co-PI

Department of Defense (DOD)
Congressionally Directed Medical Research Program (CDMRP)
A Phase I Trial of an Immune Checkpoint Inhibitor plus Stereotactic Ablative Radiotherapy (SAR) in Patients with Inoperable Stage I Non-Small Cell Lung Cancer
Specific Aim(s): This phase I/II study will determine the dose, feasibility, safety and preliminary efficacy of MPDL3280A administered with SAR in early-stage NSCLC.

UCDCC271 7/1/2018 –12/30/2022
Role: PI

Incyte
Phase I/II Trial of Epacadostat (IDO inhibitor), Intralesional SD-101 (TLR 9 agonist), and Radiotherapy in Patients with Advanced Solid Tumors and Lymphoma.
Specific Aim(s): This phase I/ II trial will determine the safety, preliminary efficacy, and changes in mechanistic immune biomarkers induced by this novel immunotherapy combination arising from my pre-clinical research.

Professional Memberships

2005 - Present	American Society of Therapeutic Radiation Oncology
2012 – Present	Society for the Immunotherapy of Cancer

Leadership & Service

Department/Section

2011 – 2020	Chair - MOSIAQ Superusers Committee
2020 – present	Department of Radiation Oncology Diversity and Racial Equity Liaison
2020 – present	Department of Radiation Oncology Global Health Liaison
2024 – present	Department of Radiation Oncology, Director of Radiation Biology

School/College/Division

2011 – present	Sarcoma Innovation Group
2011 – present	GI Cancer Innovation group

2014 – present	Lung Cancer Innovation group
2015 – present	CTSC KL2 Selection Committee
2016 – present	Phase I Trials Working Group
2016 – 2021	CCSG Staff Investigator for Immunotherapy
2019 – 2020	Chair, Stowell Chair in Pathology Search Committee
2021 – present	Director, Cancer Immunology and Energetics Program
2022 – present	Poster Reviewer – UCDCC Young Investigators Research Forum
2022 – present	Poster Reviewer – UCDCC Annual Research Symposium

National

2012 – Present	NCI – NRG Oncology Sarcoma Committee
2014 –Present	NCI –NRG Oncology Immunotherapy Committee
2015 – 2022	CTEP PD-L1 development project team
2015 – Present	NCI – Radiation Immune Modulation Working Group
2016 – 2017	ASTRO-SITC Immunotherapy in Radiation Oncology Workshop planning committee
2016 – 2019	CTEP Clinical Trial Design and Immuno-oncology Agent Working Group
2017 – Present	NCI – Gastrointestinal Malignancy Working Group
2018 – 2022	NCI – NRG Oncology Lung Committee
2018 – Present	NCI – NRG Oncology Developmental Therapeutics Committee
2019 – 2023	RSNA Radiation Oncology Study Section
2019 – 2022	NCI – Co-Chair, NRG Oncology Immunotherapy Committee
2019 – Present	ASTRO Annual Meeting abstract reviewer
2019, Nov	United Kingdom Medical Research Council – Grant Reviewer
2020, Oct	NCI – Program Project (P01) Review SEP
2021, Jun	NCI – Program Project (P01) Review SEP
2022 - present	NCI – R21 / R03 Review Panel

2022 - present	IOTN Immuno-Radiotherapy Working Group
2023 - present	NCI – R35 (Outstanding Investigator Award) Review Panel
2023 - 2024	NCI-IOTN-SITC-AAI Workshop on Combining Immunotherapy with Radiotherapy. Conference Organizing Committee.
2024 – present	NCI/NIH – TIR study section

Advisory Boards & Consulting

2017 – Present	Astra-Zeneca Immuno-Oncology Advisory Board
2017 – 2021	Incyte Immuno-Oncology Biomarkers Advisory Board
2018 – 2021	Dynavax Advisory Board
2018 – 2021	BMS Immuno-oncology delivery Advisory Board
2019 – 2022	Zosano Pharma Consultant
2020 – 2023	MultiplexThera Advisory Board
2022	Mayo Clinic Cancer Center Heavy Particle Strategic Planning Retreat
2023 – Present	Be the Healing, Inc. - Board of Directors

Editorial Responsibilities

Peer Review:

Nature Biotechnology, Nature Communications, Practical Radiation Oncology, Journal of Clinical Oncology, Cancer Research, Cancer Immunology Research, International Journal of Radiation Oncology Biology Physics, Biology of Blood and Marrow Transplantation, PLoS One, Journal for Immunotherapy of Cancer, Frontiers in Oncology, Cancers, and Radiation Research.

Teaching & Mentoring (See Statement of Teaching/Mentoring for full detail)

Formal Teaching

- Didactic lectures: Radiation Oncology – Residency training program didactics in Gastrointestinal malignancies and Sarcomas
- Didactic lectures: Radiation Biology – Basic Science radiobiology didactics for medical and physics residents.
- Didactic lectures: Cancer Immunology – (IMM 203) Graduate level course in immunology

- Didactic lectures: Cancer Nutrition – (Nutrition 116B) Upper level undergraduate course in nutrition
- Medical Student Teaching (PMD 493) – Interdisciplinary Study of Gastrointestinal Cancer
- Didactic lectures: Obesity, Cancer and Immunity – GGNB Seminar, Graduate Group in Nutritional Biology Seminar Series
- Didactic lectures: Introduction to Clinical Radiation Oncology – Howard Hughes Medical Institute Integrating Medicine in Basic Science (HHMI-IMBS)
- Prep Medico – Formal mentoring and clinical teaching for Latino undergraduate students interested in medicine.

Journal Clubs Facilitated

- High Impact Oncology Journal Club – quarterly
- Cancer Immunology Journal Club - weekly

Meetings Facilitated

- Cancer Immunology lab meeting – weekly
- Immunotherapy group meeting – weekly
- Graduate Student Works in Progress – monthly
- Radiation Oncology Gastrointestinal / Sarcoma Service Meeting – weekly
- Radiation Oncology Chart Rounds – twice weekly

Mentoring / Informal Teaching

- Mentoring of Residents
- Mentoring of Graduate Students
- Mentoring of Medical Students
- Mentoring of Undergraduate Students
- Thesis dissertation committees

Oral Presentations & Invited Lectureships

- 1997 **A.M. Monjazeb**, L. Mendoza L, N. Shastri. Identification of minor histocompatibility antigens in mice. Honors Research Symposium, University of California. Berkeley.
- 2009 **A.M. Monjazeb**, G. Riedlinger, M. Mattern, M. Aklilu, D.B. Fried, K.R. Geisinger, G. Mishra, A. Thomas, E.A. Levine, A.W. Blackstock. Outcomes of Esophageal Cancer

- Patients Staged with 18-F-FDG-PET: Can Post-chemo-radiotherapy PET Predict the Utility of Resection? *International Journal of Radiation Oncology Biology Physics*, 75(3): S164. Presented at ASTRO annual meeting.
- 2010 A.M. Monjazebl. Management of T3N0 Rectal Cancer (Panel Discussion). International Society for Gastrointestinal Oncology annual meeting.
- 2011 A. Attia, T. Vern-Gross, P. K. Garg, S. Garg, A. Thomas, H. Smith, **A. M. Monjazebl**, A. W. Blackstock. The Utility of 11C-choline Positron Emission Tomography Computerized Tomography (PET-CT) for Staging Locally Advanced Esophageal Cancer. *International Journal of Radiation Oncology Biology Physics*, 81(2): S314. Presented at ASTRO annual meeting.
- 2011 S. K. Yi, W. Mak, C. C. Yang, T. Liu, J. Cui, A. M. Chen, J. Purdy, **A. Monjazebl**, L. Do. Development of a Standardized Method for Contouring the Lumbosacral Plexus: A Preliminary Dosimetric Analysis of this Organ at Risk among 15 Patients Treated with IMRT for Lower Gastrointestinal Cancers and the Incidence of Radiation Induced Lumbosacral Plexopathy. *International Journal of Radiation Oncology Biology Physics*, 81(2): S172-S173. Presented at ASTRO annual meeting.
- 2013 **A.M. Monjazebl**, M.S. Kent, S.K. Grossenbacher, G. Sckisel, W. Culp, A.E. Zamora, A. Mirsoian, R. Canter, E.E. Sparger, W.J. Murphy. Combined Radiation Therapy and Immunotherapy Using CPG Oligodeoxynucleotides and Indolamine 2,3 Dioxygenase (IDO) Blockade. *International Journal of Radiation Oncology Biology Physics*, 87(2): S111. Presented at ASTRO annual meeting.
- 2014 **A.M. Monjazebl**. Rebound Immune Suppression. Invited Guest Lecturer at Earl Chiles Research Institute.
- 2014 **A.M. Monjazebl**. Immunomodulatory effects of radiotherapy. Invited Guest Lecturer at Wake Forest University Department of Radiation Oncology.
- 2015 **A.M. Monjazebl**. Rebound Immune Suppression. Presented at NRG Oncology Immunotherapy Educational Session.
- 2016 **A.M. Monjazebl**. Immunomodulatory effects of radiotherapy. Presented at AACR- IASCL Lung Cancer Conference.
- 2016 **A.M. Monjazebl**. Immune Biomarkers in Radiation Oncology. Presented at Radiosurgery Society annual meeting.
- 2016 **A.M. Monjazebl**. Radiotherapy in combination with dual checkpoint blockade. Presented at ECOG Fall meeting.
- 2017 **A.M. Monjazebl**. Immunotherapy for colorectal malignancies. Presented to NCI colon task force at ASCO GI.

- 2017 **A.M. Monjazeb.** Soft Tissue Sarcoma Tumor Board. Expert panel member at Society for Surgical Oncology annual meeting.
- 2017 **A.M. Monjazeb.** Radiotherapy Immune Biomarkers. Presented at ASTRO/SITC Radiotherapy and Immunotherapy meeting.
- 2017 JS Mayadev, CS Li, BA Dyer, **AM Monjazeb**, RK Valicenti, ME Daly. Prospective Randomized Control Trial Investigating the Impact of a Physician Communicated Radiation Therapy Plan Review on Breast Cancer Patient-Reported Satisfaction. International Journal of Radiation Oncology• Biology• Physics 99 (2), S40. Presented at ASTRO Annual Meeting.
- 2017 HM McGee, ME Daly, JS Mayadev, RC Fragoso, SSD Rao, RK Valicenti, K Kelly, WJ Murphy, EM Maverakis, **AM Monjazeb**. Peripheral Blood Immunophenotyping Following Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology• Biology• Physics 99 (2), S164. Presented at ASTRO Annual Meeting.
- 2018 **AM Monjazeb.** GI malignancy panelist. The 18th Multidisciplinary Management of Cancers: A Case-based Approach.
- 2018 **AM Monjazeb.** Combinatorial Immunotherapy Strategies. Presented at the California Cancer Consortium annual meeting.
- 2018 **AM Monjazeb.** Immunomodulatory Effects of Radiotherapy. Presented at AAPM national meeting.
- 2018 **AM Monjazeb.** Companion Canines as a Model for Translational Cancer Research. Presented at the United States Congressional Briefing on behalf of the AAVM.
- 2018 **AM Monjazeb.** Advances in Radiation Oncology. Presented at the 2018 19th Annual Advances in Oncology Meeting.
- 2018 **AM Monjazeb.** Paradoxical Effects of Inflammation on Cancer Immunotherapy. Invited Guest Lecturer at the University of Pennsylvania Department of Radiation Oncology Grand Rounds.
- 2019 **AM Monjazeb.** The Cancer Immunotherapy Program at UC Davis. 37th Annual JP Morgan Healthcare Conference. San Francisco, CA.
- 2019 **AM Monjazeb.** Paradoxical Effects of Inflammation on Cancer Immunotherapy. Invited Guest Lecturer at the City of Hope Cancer Center Annual Retreat. Duarte, CA.
- 2019 **AM Monjazeb.** GI malignancy panelist. The 19th Multidisciplinary Management of Cancers: A Case-based Approach. Sacramento, CA.
- 2019 **AM Monjazeb.** Effects of Obesity on Response to Checkpoint Inhibition. Presented at the July 2019 NRG meeting. Philadelphia, PA.

- 2019 **AM Monjazebl.** Paradoxical Effects of Inflammation on Cancer Immunotherapy. Invited Speaker at the West China Society for Radiation and Clinical Oncology. Xi'an, China.
- 2019 **AM Monjazebl.** Advances in Cancer Immunotherapy. Invited Speaker at the California Cancer Consortium annual meeting. Pasadena, CA.
- 2019 **AM Monjazebl.** Paradoxical Effects of Inflammation on Cancer Immunotherapy. Invited Speaker at the Rutgers 4R Symposium. New Brunswick, NJ.
- 2019 **AM Monjazebl.** Effects of Obesity on Cancer Immunotherapy. Invited Speaker at the BioCanRx Summit for Cancer Immunotherapy. Victoria, BC, Canada.
- 2019 **AM Monjazebl.** Effects of Obesity on Response to Checkpoint Inhibition. Invited Speaker at the ESMO Immuno-Oncology Congress 2019. Geneva, CH.
- 2020 **AM Monjazebl.** Effects of Obesity on Response to Checkpoint Inhibition. Invited Speaker at Roswell Park Cancer Institute. Buffalo, NY.
- 2020 **AM Monjazebl.** GI malignancy panelist. The 21st Annual Advances in Oncology Conference. Sacramento, CA.
- 2021 **AM Monjazebl.** Management of GI malignancies. The 21st Multidisciplinary Management of Cancers. Napa, CA
- 2021 **AM Monjazebl.** Immunotherapy, Immune Response and Inflammation, Session Moderator. ASTRO Annual Meeting. Chicago, IL
- 2021 **AM Monjazebl.** Spontaneous canine malignancies as a translational model for novel immunotherapy strategies. Invited Speaker at AACR Annual Meeting 2021. Virtual.
- 2022 **AM Monjazebl.** Management of GI malignancies. The 22st Multidisciplinary Management of Cancers. Napa, CA
- 2022 **AM Monjazebl.** Paradoxical Effects of Inflammation on Cancer Immunotherapy. Invited Lecture at the University of Utah Huntsman Cancer Institute. Salt Lake City, UT
- 2022 **AM Monjazebl.** GI malignancy panelist. The 23rd Advances in Oncology Conference. Sacramento, CA
- 2022 **AM Monjazebl.** Biomarkers, Tumor Biology and Radiation Response, Session Moderator. ASTRO Annual Meeting. San Antonio, TX
- 2022 **AM Monjazebl.** Management of Soft Tissue Sarcomas. Keynote lecture at the 2022 ACVR annual meeting. Reno, NV
- 2022 **AM Monjazebl.** Immunophenotyping at Time of Initial Diagnosis of Advanced Stage Cancer. ANCO Precision Oncology Symposium. San Francisco, CA
- 2022 **AM Monjazebl.** Immunomodulatory Effects of Particle and Photon Radiotherapy. Invited seminar at GSI Helmholtzzentrum für Schwerionenforschung. Darmstadt, DE.

- 2023 **AM Monjazebl.** Management of GI malignancies. The 23rd Multidisciplinary Management of Cancers. Napa, CA
- 2023 **AM Monjazebl.** Radiotherapy and Immune Modulation. Invited Lecture. Hong Kong University, Hong Kong, China.
- 2023 **AM Monjazebl.** Innate Immunity and Tumor Microenvironment, Session Moderator. ASTRO Annual Meeting. San Diego, CA.
- 2023 **AM Monjazebl.** Radiation and Immunotherapy Combination Strategies. MOASC-ANCO Immuno-Oncology Symposium. Santa Monica, CA
- 2024 **AM Monjazebl.** NCI-IOTN-SITC-AAI Workshop on Combining Immunotherapy with Radiotherapy. Conference Organizing Committee and Speaker. Bethesda, MD
- 2024 **AM Monjazebl.** Management of GI malignancies. The 24rd Multidisciplinary Management of Cancers. Napa, CA
- 2024 **AM Monjazebl.** Is Radiation a Sensitizer to Immunotherapy in Lung Cancer? Binaytara Foundation Napa Valley Lung Cancer Conference.

Bibliography (h-index: 41, i10-index: 79)

Peer Reviewed Journals

1. 2002 Clay CE, **Monjazebl A**, Thorburn J, Chilton FH, High KP. 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res, 2002 Nov; 43(11): 1818-28.
2. 2002 **Monjazebl AM**, Clay CE, High KP, Chilton FH. Antineoplastic properties of arachidonic acid and its metabolites. Prostaglandins Leukot Essent Fatty Acids, 2002 Jan; 66(1): 5-12.
3. 2004 **Monjazebl A**, Stanton C, Levine EA. Intussusception secondary to metastasis from a low-grade retroperitoneal liposarcoma. 2004 Sep; Am Surg, 70(9): 775-8.
4. 2005 **Monjazebl AM**, High KP, Koumenis C, Chilton FH. Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells. 2005 Dec; Prostaglandins Leukot Essent Fatty Acids, 73(6): 463-74.
5. 2006 **Monjazebl AM**, High KP, Connoy A, Hart LS, Koumenis C, Chilton FH. Arachidonic acid-induced gene expression in colon cancer cells. 2006 Oct; Carcinogenesis, 27(10): 1950-60.
6. 2009 Kim C, **Monjazebl AM**, Suntharalingam M, Giesinger KR, Blackstock AW. Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer. Clin Adv Hematol Oncol, 2009 May; 7(5): 327-333, 342.

7. 2010 Sanders AM, Stehle JR, Blanks MJ, Riedlinger G, Kim-Shapiro JW, **Monjazebl AM**, Adams JM, Willingham MC, Cui Z. Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements. 2010 Mar 31; BMC Cancer, 10: 121.
8. 2010 **Monjazebl AM**, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW. Outcomes of patients with esophageal cancer staged with [18-F]fluorodeoxyglucose positron emission tomography (FDG-PET): can post chemoradiotherapy FDG-PET predict the utility of resection? 2010 Nov 1; J Clin Oncol, 28(31): 4714-21.
9. 2011 Samuelian JM, Attia AA, Jensen CA, **Monjazebl AM**, Blackstock AW KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG. Treatment of Hemoptysis Associated with Aspergilloma Using External Beam Radiotherapy: A Case Report and Literature Review. Practical Radiation Oncology, 2011 Oct-Dec; 1(4): 279-281.
10. 2012 **Monjazebl AM**, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, McMullen KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG. A Phase I Dose Escalation Study of Hypofractionated IMRT Field-in-Field Boost for Newly Diagnosed Glioblastoma Multiforme. 2012 Feb 1; Int J Radiat Oncol Biol Phys, 82(2): 743-8
11. 2012 Yi SK, Mak W, Yang CC, Liu T, Ph.D., Cui J, Chen AM, Purdy JA, **Monjazebl AM***, Do L. Development of a Standardized Method for Contouring the Lumbosacral Plexus: A Preliminary Dosimetric Analysis of this Organ at Risk Among 15 Patients Treated with IMRT for Lower Gastrointestinal Cancers and the Incidence of Radiation Induced Lumbosacral Plexopathy. 2012 Oct 1; Int J Radiat Oncol Biol Phys, 84(2): 376-82.
* **Corresponding Author**
12. 2012 Kimple RJ, Russo S, **Monjazebl A**, Blackstock AW. The Role of Chemoradiation for Patients with Resectable or Potentially Resectable Pancreatic Cancer. Expert review of anticancer therapy, 2012 Apr; 12(4): 469-80
13. 2012 **Monjazebl AM**, Hsiao HH, Sckisel GD, Murphy WJ. The Role of Antigen-Specific and Nonspecific Immunotherapy in the Treatment of Cancer. 2012 Jul-Sep; J Immunotoxicol, 9(3): 248-58
14. 2012 Shah D, Borys D, Martinez SR, Li CS, Tamurian RM, Bold RJ, **Monjazebl A**, Canter RJ. Complete Pathologic Response to Neoadjuvant Radiotherapy is Predictive of Oncological Outcome in Patients with Soft Tissue Sarcoma. 2012 Sep; Anticancer Res, 32(9):3911-5
15. 2012 Bouchlaka MN, Sckisel GD, Wilkins D, Maverakis E, **Monjazebl AM**, Fung M, Welniak L, Redelman D, Fuchs A, Evrensel CA, Murphy WJ. Mechanical Disruption of Tumors by Iron Particles and Magnetic Field Application Results in Increased Anti-Tumor Immune Responses. PLoS One. 2012; 7(10):e48049
16. 2013 **Monjazebl AM**, Blackstock AW. The impact of multimodality therapy of distal

- esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. *Semin Radiat Oncol.* 2013 Jan; 23(1):60-73
17. 2013 Wasif N, Smith CA, Tamurian RM, Christensen SD, **Monjaze** AM, Martinez SR, Canter RJ. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. *JAMA Surg.* 2013 Jul; 148(7):632-9
 18. 2013 **Monjaze** AM, Zamora AE, Grossenbacher SK, Mirsoian A, Sckisel GD, Murphy WJ. Immunoediting and antigen loss: overcoming the Achilles heel of immunotherapy with antigen non-specific therapies. *Front Oncol.* 2013 Jul 26; 3:197
 19. 2013 Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, Wilkins DE, Alderson KL, Hsiao HH, Weiss JM, **Monjaze** AM, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltout RH, Redelman D, Taub DD, Murphy WJ. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. *J Exp Med.* 2013 Oct 21; 210(11): 2223-37
 20. 2014 Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, **Monjaze** AM. Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. *Ann Surg Oncol.* 2014 May; 21(5):1616-23
 21. 2014 Kao C, Wurz GT, **Monjaze** AM, Vang DP, Cadman TB, Griffey SM, Wolf A, DeGregorio MW. Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model. *Cancer Immunol Res.* 2014 Jun; 2(6): 581-9
 22. 2014 Pai CC, Hsiao HH, Sun K, Chen M, Hagino T, Tellez J, Mall C, Blazar BR, **Monjaze** A, Abedi M, Murphy WJ. Therapeutic benefit of bortezomib on acute GVHD is tissue specific and is associated with IL-6 levels. *Biol Blood Marrow Transplant.* 2014 Dec; 20(12):1899-904.
 23. 2014 **Monjaze** AM, Tietze JK, Grossenbacher SK, HsiaoH, Zamora AE, Mirsoian A, Koehn B, Blazar BR, Weiss JM, Wiltout RH, Sckisel GD, Murphy WJ. Bystander Activation and Anti-Tumor effects of CD8+ T cells Following Interleukin-2 Based Immunotherapy is Independent of CD4+ T cell Help. *PLoS One.* 2014 Aug 13; 9(8):e102709.
 24. 2014 Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ, **Monjaze** AM, Murphy WJ. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. *BMC Cancer.* 2014 Oct 10; 14(1):756.
 25. 2014 Wong P, Houghton P, Kirsch DG, Finkelstein SE, **Monjaze** AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Wang D. Combining Targeted Agents with Modern Radiotherapy in Soft Tissue Sarcomas. *J Natl Cancer Inst.* 2014 Oct 18; 106(11).

26. 2014 Mirsoian A, Bouchlaka MN, Sckisel GD, Chen M, **Monjazez AM**, Spencer R, Fishbein K, Siddiqui S, Martin B, Maudsley S, Hesdorffer C, Ferrucci L, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltout RH, Taub DD, Murphy WJ. Adiposity Induces Lethal Cytokine Storm Following Systemic Administration of Stimulatory Immunotherapy Regimens in Aged Mice. *J Exp Med*. 2014 Nov 17; 211(12):2373-83.
27. 2015 Naing BA, **Monjazez AM**, Li CS, Lee LY, Yang A, Borys D, Canter RJ. Perioperative Radiotherapy is Associated with Improved Survival among Patients with Synovial Sarcoma: A SEER Analysis. *J Surg Oncol*. 2015 Feb;111(2):158-64.
28. 2015 Yuen NK, Li CS, **Monjazez AM**, Borys D, Bold RJ, Canter RJ. Older age impacts radiotherapy-related outcomes in soft tissue Sarcoma. *J Surg Res*. 2015 Jun 16; pii: S0022-4804(15)00703-9.
29. 2015 Perks JR, Lucero S, **Monjazez AM**, Li JJ. Anthropomorphic phantoms for Confirmation of Linear Accelerator-Based Small Animal Irradiation. *Cureus*. 2015 Mar 5;7(3):e254.
30. 2015 Ames E, Canter RJ, Smith RC, Hagino T, Mac S, Perez-Cunningham J, Grossenbacher SK, Sckisel GD, Urayama S, **Monjazez AM**, Fragoso RC, Sayers TJ, Murphy WJ. Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. *Oncoimmunology*. 2015 June 5;4(9):e1036212.
31. 2015 Mall C, Sckisel GD, Proia DA, Mirsoian A, Grossenbacher SK, Pai CC, Chen M, **Monjazez AM**, Kelly K, Blazar BR, Murphy WJ. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. *Oncoimmunology*. 2015 Aug 12;5(2):e1075114.
32. 2015 Sckisel GD, Bouchlaka MN, **Monjazez AM**, Crittenden M, Curti BD, Wilkins DE, Alderson KA, Sungur CM, Ames E, Mirsoian A, Reddy A, Soulika A, Weiss JM, Blazar BR, Longo DL, Wiltout RH, Murphy WJ. Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-cell Dependent Immunity. *Immunity*. 2015 Aug 18;43(2):240-50.
33. 2015 Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, **Monjazez AM**, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Completed response rate in patients with cutaneous metastatic melanoma treated with intralesional IL-2, imiquimod, and topical retinoid combination therapy: Results of a case series. *J Am Acad Dermatol*. 2015 Aug 7; pii:S0190-9622(15)01866-6.
34. 2015 Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, **Monjazez AM**, Fragoso RC, Sayers TJ, Murphy WJ. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. *J Immunol*. 2015 Oct 15;195(8):4010-9.
35. 2015 Daly ME, **Monjazez AM**, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2015 Dec;10(12):1685-93
36. 2015 Dyer BA, Kahn LA, Matin M, Bold RJ, Tanaka MI, **Monjazez AM**. Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma. *Cureus*. 2015 Dec 15;7(12):e406

37. 2016 **Monjazebl AM**, Schoenfeld JD. Radiation dose and checkpoint blockade immunotherapy: unanswered questions. *Lancet Oncol.* 2016 Jan;17(1):e3-4
38. 2016 **Monjazebl AM**, Kent MS, Grossenbacher SK, Mall C, Zamora AE, Mirsoian A, Chen M, Kol A, Shia SL, Reddy A, Perks RJ, Culp W, Sparger EE, Canter R, Sckisel G, Murphy WJ. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Anti-tumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. *Clin Cancer Res.* 2016 Sep 1;22(17):4328-40.
39. 2016 Yuen NK, Li CS, **Monjazebl AM**, Borys D, Bold RJ, Canter RJ. Older Age Modifies Oncologic Outcome Following Radiotherapy in Soft-tissue Sarcoma: A Subtype-specific SEER Analysis. *Anticancer Res.* 2016 Apr;36(4):1745-50.
40. 2016 Miyamoto J, Michaud AL, Harandi NK, Kim EJ, Semrad T, Khatri V, Mayadev J, Perks J, **Monjazebl AM**. The Role of Image-guided Radiotherapy in the Treatment of Anorectal Cancer Using Prone Belly-board Positioning. *Anticancer Res.* 2016 Jun;36(6):3013-7.
41. 2016 Park JS, Nakache YP, Katz J, Boutin RD, Steffner RJ, **Monjazebl AM**, Canter RJ. Conservative management of desmoid tumors is safe and effective. *J Surg Res.* 2016 Sep;205(1):115-20.
42. 2017 Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JJ, Culp WT, Sparger EE, Rebhun RB, **Monjazebl AM**, Murphy WJ, Canter RJ. Canine cancer immunotherapy studies: linking mouse and human. *J Immunother Cancer.* 2016 Dec 20;4:97
43. 2017 Silvestrini MT, Ingham ES, Mahakian LM, Kheirrolomoom A, Liu Y, Fite BZ, Tam SM, Tucci ST, Watson KD, Wong AW, **Monjazebl AM**, Hubbard NE, Murphy WJ, Borowsky AD, Ferrara KW. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. *JCI Insight.* 2017 Mar 23;2(6):e90521.
44. 2017 Sckisel GD, Mirsoian A, Minnar CM, Crittenden M, Curti B, Chen JQ, Blazar BR, Borowsky AD, **Monjazebl AM**, Murphy WJ. Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. *J Immunother Cancer.* 2017 Apr 18;5:33
45. 2017 Gingrich AA, Bateni SB, **Monjazebl AM**, Darrow MA, Thorpe SW, Kirane AR, Bold RJ, Canter RJ. Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis. *Ann Surg Oncol.* 2017 Oct;24(11):3252-3263.
46. 2017 Mehnert JM, **Monjazebl AM**, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The Challenge for Development of Valuable Immuno-oncology Biomarkers. *Clin Cancer Res.* 2017 Sep 1;23(17):4970-4979.
47. 2017 Day D, **Monjazebl AM**, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. *Clin Cancer Res.* 2017 Sep 1;23(17):4980-4991.
48. 2017 Baird JR, **Monjazebl AM***, Shah O, McGee H, Murphy WJ, Crittenden MR, Gough MJ. Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. *Int*

49. 2017 Canter RJ, Grossenbacher SK, Foltz JA, Sturgill IR, Park JS, Luna JI, Kent MS, Culp WTN, Chen M, Modiano JF, **Monjazebl AM**, Lee DA, Murphy WJ. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. J Immunother Cancer. 2017 Dec 19;5(1):98.
50. 2018 Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, **Monjazebl AM**, Shiao SL, Tran PT, Ahmed MM. Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop. J Immunother Cancer. 2018 Jan 29;6(1):6
51. 2018 Henderson T, Chen M, Darrow MA, Li CS, Chiu CL, **Monjazebl AM**, Murphy WJ, Canter RJ. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. Journal of surgical research. 2018 Mar 1: 223, 207-214
52. 2018 Yanagisawa M, Gingrich AA, Judge S, Li CS, Wang N, Thorpe SW, Kirane AR, Bold RJ, **Monjazebl AM**, Canter RJ. Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft Tissue Sarcoma. Anticancer Res. 2018 Mar;38(3):1491-1497.
53. 2018 Ogawa H, Luxardi G, Kirane A, Kulkarni R, **Monjazebl AM**, Cheng MY, Ma C, Maverakis E. T cells dominate the local immune response induced by intralesional IL-2 in combination with imiquimod and retinoid for in-transit metastatic melanoma. J Invest Dermatol. 2018 Jun;138(6):1442-1445.
54. 2018 Chavez M, Silvestrini MT, Ingham ES, Fite BZ, Mahakian LM, Tam SM, Ilovitsh A, **Monjazebl AM**, Murphy WJ, Hubbard NE, Davis RR, Tepper CG, Borowsky AD, Ferrara KW. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Theranostics. 2018 Jun 7;8(13):3611-3628.
55. 2018 McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Frago RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, **Monjazebl AM**. Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1259-1270.
56. 2018 Withers SS, Moore PF, Chang H, Choi JW, McSorley SJ, Kent MS, **Monjazebl AM**, Canter RJ, Murphy WJ, Sparger EE, Rebhun RB. Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol. 2018 Oct;87:64-74
57. 2019 Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahim S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, **Monjazebl AM**. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 Jan;25(1):141-151.

58. 2019 Wang Z, **Monjaze** AM, Murphy WJ. The Complicated Effects of Obesity on Cancer and Immunotherapy. *Immunotherapy*. 2019 Jan;11(1):11-14.
59. 2019 Withers SS, Skorupski KA, York D, Choi JW, Woolard KD, Laufer-Amorim R, Sparger EE, Rodriguez CO, McSorley SJ, **Monjaze** AM, Murphy WJ, Canter RJ, Rebhun RB. Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. *Vet Comp Oncol*. 2019 Mar;17(1):49-60.
60. 2019 Nguyen KNB, Hause DJ, Novak J, **Monjaze** AM, Daly ME. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors. *Pract Radiat Oncol*. 2019 Mar;9(2):e196-e202
61. 2019 Saiz AM Jr, Gingrich AA, Canter RJ, Kirane AR, **Monjaze** AM, Randall RL, Thorpe SW. Role of Radiation Therapy in Adult Extraskelatal Ewing's Sarcoma Patients Treated with Chemotherapy and Surgery. *Sarcoma*. 2019 Apr 24;2019:5413527.
62. 2019 Gingrich AA, Bateni SB, **Monjaze** AM, Thorpe SW, Kirane AR, Bold RJ, Canter RJ. Extremity soft tissue sarcoma in the elderly: Are we overtreating or undertreating this potentially vulnerable patient population? *J Surg Oncol*. 2019 Jun;119(8):1087-1098
63. 2019 Dyer BA, Li CS, Daly ME, **Monjaze** AM, Mayadev JS. Prospective, Randomized Control Trial Investigating the Impact of a Physician-Communicated Radiation Therapy Plan Review on Breast Cancer Patient-Reported Satisfaction. *Pract Radiat Oncol*. 2019 Nov;9(6):e487-e496.
64. 2019 Naik A, **Monjaze** AM, Decock J. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. *Front Immunol*. 2019 Aug 14;10:1940.
65. 2019 George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, **Monjaze** AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. *Cancer*. 2019 Aug 15;125(16):2732-2746.
66. 2019 Withers SS, York D, Choi JW, Woolard KD, Laufer-Amorim R, Sparger EE, Burton JH, McSorley SJ, **Monjaze** AM, Murphy WJ, Canter RJ, Rebhun RB. Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma. *Vet Comp Oncol*. 2019 Sep;17(3):242-252.
67. 2019 Judge SJ, Lata-Arias K, Yanagisawa M, Darrow MA, **Monjaze** AM, Kirane AR, Bold RJ, Canter RJ, Canter DJ. Morbidity, mortality and temporal trends in the surgical management of retroperitoneal sarcoma: An ACS-NSQIP follow up analysis. *J Surg Oncol*. 2019 Sep;120(4):753-760.
68. 2019 Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, Burugapalli B, **Monjaze** AM, Hendifar AE, Hitchins M, Klempner SJ, Cho M. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. *Clin Colorectal Cancer*. 2019 Dec;18(4):307-309.
69. 2020 Chen H, Nguyen KNB, Huang H, Feng C, Zhao X, Daly ME, Rao S, Fragos R,

Valicenti R, Sekhon S, Navarro SM, Kim EJ, Cho M, Tam K, Farkas L, Halabi WJ, **Monjazez AM***, Rong Y. Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. *Pract Radiat Oncol*. 2020 Sep-Oct;10(5):e372-e377.

* **Corresponding author, Co-Senior Author**

70. 2020 Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, **Monjazez AM**, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. *PLoS One*. 2020 Feb 21;15(2):e0224775
71. 2020 Judge SJ, Dunai C, Aguilar EG, Vick SC, Sturgill IR, Khuat LT, Stoffel KM, Van Dyke J, Longo DL, Darrow MA, Anderson SK, Blazar BR, **Monjazez AM**, Serody JS, Canter RJ, Murphy WJ. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. *J Clin Invest*. 2020 Jun 1;130(6):3051-3068.
72. 2020 **Monjazez AM**, Schalper KA, Villarroel-Espindola F, Nguyen A, Shiao SL, Young K. Effects of Radiation on the Tumor Microenvironment. *Semin Radiat Oncol*. 2020 Apr;30(2):145-157.
73. 2020 Gingrich AA, Marrufo AS, Liu Y, Li CS, Darrow MA, **Monjazez AM**, Thorpe SW, Canter RJ. Radiotherapy is Associated with Improved Survival in Patients with Synovial Sarcoma Undergoing Surgery: A National Cancer Database Analysis. *J Surg Res*. 2020 Nov;255:378-387.
74. 2020 Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, Louie R, Tam K, Gholami S, Halabi W, **Monjazez A**, Dayyani F, Cho M. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. *J Natl Compr Canc Netw*. 2020 Jul;18(7):798-804.
75. 2020 Candas-Green D, Xie B, Huang J, Fan M, Wang A, Mena C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, **Monjazez AM**, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. *Nat Commun*. 2020 Sep 14;11(1):4591
76. 2020 Judge SJ, Darrow MA, Thorpe SW, Gingrich AA, O'Donnell EF, Bellini AR, Sturgill IR, Vick LV, Dunai C, Stoffel KM, Lyu Y, Chen S, Cho M, Rebhun RB, **Monjazez AM**, Murphy WJ, Canter RJ. Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. *J Immunother Cancer*. 2020 Nov;8(2):e001355.
77. 2020 Le CT, Khuat LT, Caryotakis S, Wang M, Dunai C, Nguyen AV, Vick L, Stoffel KS, Blazar B, **Monjazez AM**, Murphy WJ, Soulika A. PD-1 blockade reverses obesity-mediated T-cell priming impairment. *Front Immunol*. 2020 Oct 29;11:590568.
78. 2020 Khuat LT, Le CT, Pai CC, Shields-Cutler R, Holtan S, Rashidi A, Parker SL, Knights D, Luna JI, Dunai C, Wang Z, Sturgill IR, Stoffel K, Merleev AA, More SK, Maverakis E, Raybould H, Chen M, Canter RJ, **Monjazez AM**, Dave M, Ferrara JLM, Levine JE,

- Longo DL, Abedi M, Blazar BR, Murphy WJ. Obesity and Microbiome Alterations Augments Acute Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. *Sci. Trans. Med.* 2020 Nov 25;12(571):eaay7713.
79. 2020 McGee HM, Marciscano AE, Campbell AM, **Monjazez AM**, Kaech SM, Teijaro JR. Parallels between the anti-Viral State and the Irradiated State. *J Natl Cancer Inst.* 2020 Nov 30:djaa190.
 80. 2020 Chen H, Shi L, Nguyen KNB, **Monjazez AM**, Matsukuma KE, Loehfelm TW, Huang H, Qiu J, Rong Y. MRI Radiomics for Prediction of Tumor Response and Downstaging in Rectal Cancer Patients after Preoperative Chemoradiation. *Adv Radiat Oncol.* 2020 May 11;5(6):1286-1295
 81. 2021 **Monjazez AM**, Wang Z, Vick LV, Dunai C, Khuat LT, Mall C, Murphy WJ. Limitations of Preclinical Cancer Immunotherapy Modeling Involving Anti-PD1 Therapies: The Need for Mouse Reagents in Determining Both Efficacy and Toxicities. *Cancers (Basel).* 2021 Feb 10;13(4):729.
 82. 2021 **Monjazez AM**, Giobbie-Hurder A, Lako A, Thrash EM, Brennick RC, Kao KZ, Manuszak C, Gentzler RD, Tesfaye A, Jabbour SK, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon HJ, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjjatic S, Maverakis E, Marusina AI, Merleev AA, Severgnini M, Pfaff KL, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig SJ, Hodi FS, Schoenfeld JD. A Multicenter Randomized Phase 2 Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. *Clin Cancer Res.* 2021 May1;27(9):2470-2480.
 83. 2021 Demaria S, Guha C, Schoenfeld J, Morris Z, **Monjazez A**, Sikora A, Crittenden M, Shiao S, Khleif S, Gupta S, Formenti SC, Vikram B, Coleman CN, Ahmed MM. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? *J Immunother Cancer.* 2021 Apr;9(4):e002038.
 84. 2021 Khuat LT, Vick LV, Dunai C, Collins CP, More SK, Le CT, Pai CS, Stoffel KM, Maverakis E, Canter RJ, **Monjazez AM**, Longo DL, Abedi M, Choi E, Blazar BR, Dave M, Murphy WJ. Increased efficacy of dual pro-inflammatory cytokine blockade on acute GVHD while maintaining GVT effects. *Blood.* 2021 Aug 23:blood.2021011216. doi: 10.1182/blood.2021011216.
 85. 2021 Cruz SM, Basmaci UN, Bateni CP, Darrow MA, Judge SJ, **Monjazez AM**, Thorpe SW, Humphries MD, Canter RJ. Surgical and oncologic outcomes following arterial resection and reconstruction for advanced solid tumors. *J Surg Oncol.* 2021 Sep 8. doi: 10.1002/jso.26665. Online ahead of print.
 86. 2021 Khuat LT, Vick LV, Choi E, Dunai C, Merleev AA, Maverakis E, Blazar B, **Monjazez AM**, Murphy WJ. Mechanisms by which obesity promotes acute graft-versus-host disease in mice. *Front Immunol.* 2021 Oct 11;12:752484 doi:10.3389
 87. 2021 Sparger EE, Chang H, Chin N, Rebhun RB, Withers SS, Kieu H, Canter RJ, **Monjazez AM**, Kent MS. T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma. *Front Vet Sci.* 2021 Dec 2;8:772932

88. 2022 Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ; Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler R, Lee C, Hubbard J, Abbruzzese JL, Jabbour SK, Uboha N, Stephans K, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed M, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, **Monjazebl AM***, Hodi FS. Durvalumab, tremelimumab alone or in combination with low-dose or hypofractionated targeted radiotherapy in metastatic non-small cell lung cancer refractory to prior PD-1 therapy: a multicentre, open-label, randomized, phase 2 trial. *Lancet Oncology*. 2022 Feb;23(2):279-291
* **Co-Senior Author**
89. 2022 Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, Hamsafar Y, Evans AC, Huang J, Zhou W, Lin X, Ye N, Wanggou S, Chen W, Jing D, Fragoso RC, Dugger BN, Wilson PF, Coleman MA, Xia S, Li X, Sun LQ, **Monjazebl AM**, Wang A, Murphy WJ, Kung HJ, Lam KS, Chen HW, Li JJ. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. *Nat Commun*. 2022 Mar 21;12(1):1511.
90. 2022 Judge SJ, Bloomstein JD, Sholevar CJ, Darrow MA, Stoffel KM, Vick LV, Dunai C, Cruz SM, Razmara AM, **Monjazebl AM**, Rebhun RB, Murphy WJ, Canter RJ. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas. *Front Immunol*. 2022 Jul 7;13:893177.
91. 2022 Jawad MU, Zeitlinger LN, Bewley AF, O'Donnell EF 3rd, Traven SA, Carr-Ascher JR, **Monjazebl AM**, Canter RJ, Thorpe SW, Randall RL. Head and Neck Cutaneous Soft-Tissue Sarcoma Demonstrate Sex and Racial/Ethnic Disparities in Incidence and Socioeconomic Disparities in Survival. *J Clin Med*. 2022 Sep 17;11(18):5475.
92. 2022 Le ST, Ji-Xu A, Liakos W, Toussi AM, Cheng MY, Ma C, Wang EA, Wilken R, Boddu S, Downing L, Kao J, Davis JR, **Monjazebl AM**, Fung MA, Konia TH, Maverakis E, Kirane AR. Intralesional interleukin-2 augmentation therapy in treatment-refractory melanoma. *Dermatol Ther*. 2022 Nov;35(11):e15853.
93. 2023 Perry LM, Cruz SM, Kleber KT, Judge SJ, Darrow MA, Jones LB, Basmaci UN, Joshi N, Settles ML, Durbin-Johnson BP, Gingrich AA, **Monjazebl AM**, Carr-Ascher J, Thorpe SW, Murphy WJ, Eisen JA, Canter RJ. Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis. *J Immunother Cancer*. 2023 Jan;11(1):e004285. doi: 10.1136/jitc-2021-004285.
94. 2023 Vick LV, Collins CP, Khuat LT, Wang Z, Dunai C, Aguilar EG, Stoffel K, Yendamuri S, Smith R Jr, Mukherjee S, Barbi J, Canter RJ, **Monjazebl AM**, Murphy WJ. Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the "obesity paradox". *Front Immunol*. 2023 Jan 26;13:1012016. doi: 10.3389/fimmu.2022.1012016. eCollection 2022.
95. 2023 Rosario SR, Dong B, Zhang Y, Hsiao HH, Isenhardt E, Wang J, Siegel EM, **Monjazebl AM**, Owen DH, Dey P, Tabung FK, Spakowicz DJ, Murphy WJ, Edge S, Yendamuri S, Ibrahim S, Kolesar JM, McDonald PH, Vadehra D, Churchman M, Liu S, Kalinski P, Mukherjee S. Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males

- and Females with Gastrointestinal Cancers. *Int J Mol Sci.* 2023 Jun 29;24(13):10847. doi: 10.3390/ijms241310847.
96. 2023 Wang CX, Hunt J, Feinstein S, Kim SK, **Monjaze** AM. Advances in Radiotherapy Immune Modulation: From Bench-to-Bedside and Back Again. *Surg Oncol Clin N Am.* 2023 Jul;32(3):617-629. doi: 10.1016/j.soc.2023.02.009. Epub 2023 Apr 4.
 97. 2023 Cruz SM, Sholevar CJ, Judge SJ, Darrow MA, Iranpur KR, Farley LE, Lammers M, Razmara AM, Dunai C, Gingrich AA, Persky J, Mori H, Thorpe SW, **Monjaze** AM, Murphy WJ, Canter RJ. Intratumoral NKp46+ natural killer cells are spatially distanced from T and MHC-I+ cells with prognostic implications in soft tissue sarcoma. *Front Immunol.* 2023 Jul 21;14:1230534. doi: 10.3389/fimmu.2023.1230534. eCollection 2023.
 98. 2023 **Monjaze** AM, Daly ME, Luxardi G, Maverakis E, Merleev AA, Marusina AI, Borowsky A, Mirhadi A, Shiao SL, Beckett L, Chen S, Eastham D, Li T, Vick LV, McGee HM, Lara F, Garcia L, Morris LA, Canter RJ, Riess JW, Schalper KA, Murphy WJ, Kelly K. Atezolizumab plus Stereotactic Ablative Radiotherapy for Medically Inoperable Patients with Early-Stage Non-Small Cell Lung Cancer: A Multi-Institutional Phase I trial. *Nat Commun.* 2023 Sep 2;14(1):5332.
 99. 2023 Le CT, Vick LV, Collins C, Dunai C, Sheng MK, Khuat LT, Barao I, Judge SJ, Aguilar EG, Curti B, Dave M, Longo DL, Blazar BR, Canter RJ, **Monjaze** AM, Murphy WJ. Regulation of human and mouse bystander T cell activation responses by PD-1. *JCI Insight.* 2023 Sep 22;8(18):e173287. doi: 10.1172/jci.insight.173287.
 100. 2023 Vick LV, Canter RJ, **Monjaze** AM, Murphy WJ. Multifaceted effects of obesity on cancer immunotherapies: Bridging preclinical models and clinical data. *Semin Cancer Biol.* 2023 Jul 26;95:88-102. doi: 10.1016/j.semcancer.2023.07.004.
 101. 2024 Huynh JC, Cho M, **Monjaze** A, Al-Obeidi E, Singh A, Tam K, Lara F, Martinez A, Garcia L, Kim EJ. Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma. *Invest New Drugs.* 2024 Feb;42(1):35-43. doi: 10.1007/s10637-023-01416-w. Epub 2023 Dec 1.
 102. 2024 Priester JI, Simister SK, Sario M, Choi J, Pina D, Theriault R, Bateni C, Ghasemiesfe A, Carr-Ascher J, **Monjaze** AM, Canter RJ, Randall RL, Thorpe SW. Scrutinizing the use of contrasted chest CTs in extremity sarcoma staging and surveillance. *J Surg Oncol.* 2024 Mar;129(3):523-530. doi: 10.1002/jso.27510. Epub 2023 Nov 23.
 103. 2024 Xie B, Fan M, Wang CX, Zhang Y, Xu S, Mizenko R, Lin TY, Duan Y, Zhang Y, Huang J, Berg JI, Wu D, Li A, Hao D, Gao K, Sun Y, Tepper CG, Carney R, Li Y, Wang A, Gong Q, Daly M, Jao LE, **Monjaze** AM, Fierro FA, Li JJ. Post-death Vesicles of Senescent Bone Marrow Mesenchymal Stromal Polyploids Promote Macrophage Aging and Breast Cancer. *bioRxiv [Preprint].* 2024 Mar 8:2024.03.06.583755.
 104. 2024 Cruz SM, Iranpur KR, Judge SJ, Ames E, Sturgill IR, Farley LE, Darrow MA, Crowley JS, **Monjaze** AM, Murphy WJ, Canter RJ. Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas. *Int J Mol Sci.* 2024 Mar 15;25(6):3351. doi: 10.3390/ijms25063351.
 105. 2024 Su C, Kim SK, Wang CX, Kirsch DG, **Monjaze** AM. Radiotherapy Combined with

Book Chapters

- 2009 **Monjazebl AM** and Blackstock AW: Palliative Radiotherapy, Jobe BA, Thomas CR, Hunter JC, Tran N, (ed), Esophageal Tumors: Principles and Practice, Demos Medical Publishing, New York, NY.
- 2014 Sckisel GD, **Monjazebl AM**, Mirsoian A, Zamora AE, Grossenbacher S, and Murphy WJ: Impact of ageing and body mass on cancer immunotherapy outcomes, Reese R, (ed), Tumor Immunology and Immunotherapy, Integra Publishing, Oak Brook, IL.
- 2024 Ahmed A, Wang CX, Gough M, and **Monjazebl AM**: Chapter 26: Radiation Therapy and the Immune System, Wazer DE (ed), Perez and Brady's Principles and Practice of Radiation Oncology 8th Edition, Wolters Kluwer, Philadelphia, PA.

Abstracts

- 2004 **A Monjazebl** , C Stanton, EA Levine. Intussusception secondary to metastasis from a low grade retroperitoneal liposarcoma., Poster Presentation at Southeastern Surgical Congress, Atlanta, GA.
- 2007 C. Kim, M.R. Farmer, J. Yacoub, **A. Monjazebl**, E.A. Levine, M. Aklilu, K.R. Geinsinger, G. Mishra, S. Melin, A.W. Blackstock. Tri-Modality Therapy for Esophageal Cancer: Mucinous Histology Is Associated With Decreased Pathologic Response Rates to Neoadjuvant Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 69(3): S267.
- 2007 **A.M. Monjazebl**, M.R. Farmer, M. Mattern, A. Mebea, E.A. Levine, K.R. Geisinger, G. Mishra, S. Melin, A.W. Blackstock. Patterns of Failure for Esophageal Cancer Patients Optimally Staged With 18-F-FDG-PET and Observed After Chemo-radiotherapy. International Journal of Radiation Oncology Biology Physics, 69(3): S274.
- 2008 D.B. Fried, N. Lailas, **A. Monjazebl**, F. Hendricks, S. Katz, J. Sehn, I. Kasenetz, H. Bondy, C. Ahaghotu, P.G. Koutrouvelis. Seminal Vesicle Biopsy and Prostate Brachytherapy using Three-dimensional Stereotaxis with Posterior Pararectal Approach. International Journal of Radiation Oncology Biology Physics, 72(1): S315.
- 2008 **A.M. Monjazebl**, J.D. Bourland, L.D. Case, T.L. Ellis, G.J. Lesser, K.P. McMullen, M. Munley, S.B. Tatter, E.G. Shaw. A Phase I Dose Escalation Study of IMRT Field-in-field Boost for Newly Diagnosed Glioblastoma Multiforme (GBM). International Journal of Radiation Oncology Biology Physics, 72(1): S227.
- 2010 **A. M. Monjazebl**, G. Riedlinger, S. Isom, M. Aklilu, K. R. Geisinger, G. Mishra, E. A. Levine, A. W. Blackstock. Radiotherapy for Esophageal Cancer: Does Dose Affect

- Outcomes? International Journal of Radiation Oncology Biology Physics, 78(3): S307.
- 2012 A. Gill MD, A. Brunson, P. Lara, Jr., K. Olson, **A. Monjaze**, V. Khatri MD, T.J. Semrad. Prognostic Significance of Lymph Node Retrieval In Localized Rectal Cancer: A Registry Analysis of 8,946 Patients. ASCO 2012.
 - 2012 **A.M. Monjaze**, J. Cui, M. Daly, A.M. Chen, R. Fragoso, J.A. Perks, J. Mayadev, A.L. Michaud. A Retrospective Analysis of Setup Reproducibility for Anorectal Cancer Patients Treated Prone on a Belly Board. International Journal of Radiation Oncology Biology Physics Vol. 84(3): S745.
 - 2013 A. Mirsoian, M. Bouchlaka, G. Sckisel, **A. Monjaze**, W. Murphy. Impact of age and body fat on increased toxicity following systemic immunotherapy. J Immunol 190:188.20.
 - 2013 G. Sckisel, M. Bouchlaka, A. Mirsoian, **A. Monjaze**, W. Murphy. Strong systemic immune stimulation results in profound inhibition on the generation of subsequent primary responses. J Immunol 2013 190:114.18.
 - 2013 E. Ames, R. Smith, J. Perez, **A.M. Monjaze**, R. Canter, W.J. Murphy. NK cells mediate preferential killing of cancer stem cells in solid tissue tumors. The Society for Natural Immunity. Heidelberg, Germany, May 18-22.
 - 2013 S.K. Grossenbacher, **A.M. Monjaze**, J.K. Tietze, G.D. Sckisel, A. Mirsoian, H. Hsiao, B. Koehn, D.E.C. Wilkins, B.R. Blazar, W.J. Murphy. Bystander Memory CD8 T Cell Proliferation After anti-CD40/IL-2 Treatment is Independent of CD4 T Cells. Society for the Immunotherapy of Cancer.
 - 2013 **A.M. Monjaze**, M.S. Kent, S.K. Grossenbacher, G. Sckisel, W. Culp, A.E. Zamora, A. Mirsoian, R. Canter, E.E. Sparger, W.J. Murphy. Combined Radiation Therapy and Immunotherapy for the Treatment of Metastatic Cancer. Association for Clinical and Translational Research.
 - 2014 **A. M. Monjaze**, E. Ames, W. J. Murphy, R. Canter. Radiation Induced Changes In Chemokine Expression Promote Natural Killer Cell Homing. International Journal of Radiation Oncology Biology Physics Vol. 90(1): S775.
 - 2014 **A. M. Monjaze**, E. Ames, W. J. Murphy, R. Canter. Radiation Enhances Innate Immune Recognition of Cancer Stem Cells in Solid Tumors. International Journal of Radiation Oncology Biology Physics Vol. 90(1): S808.
 - 2014 **A.M. Monjaze**, N.K. Harandi, A.L. Michaud, R. Canter, J. Perks. Analysis of Daily Setup Variation with Image-Guided Treatment of Soft-Tissue Sarcomas. International Journal of Radiation Oncology Biology Physics Vol. 90(1): S848-849.
 - 2014 S. K. Grossenbacher, E. Ames, S. Mac, R. Masoud, R. J. Canter, **A.M. Monjaze**, William J. Murphy. Enhanced Natural Killer Cell Targeting of Cancer Stem Cells Using

- 2014 KW Naing, C Li, L Lee, **AM Monjaze**, A Yang, D Borys, RJ Canter. Perioperative Radiotherapy is Associated with Improved Survival among Patients with Synovial Sarcoma: A SEER Analysis. *Journal of Surgical Research* 186 (2), 569
- 2014 RJ Canter, E Ames, S Mac, S Grossenbacher, RC Smith, J Tellez, **AM Monjaze**, M Chen, WJ Murphy Sorafenib Enriches for Cancer Stem Cells in Pre-Clinical Models of Soft Tissue Sarcoma. *Journal of Surgical Research* 186 (2), 682
- 2014 RJ Canter, C Lee, Y Nakache, C Li, D Shah, J Katz, RD Boutin, R Steffner, **AM Monjaze**. Predictors of Residual Disease following Unplanned Excision of Unsuspected Soft Tissue Sarcomas. *ANNALS OF SURGICAL ONCOLOGY* 21, S144-S145
- 2014 R.J. Canter, D. Borys, A. Olusanya, C. Li, L. Lee, R.D. Boutin, S.D. Christensen, R.M. Tamurian, **A.M. Monjaze**. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. *Annals of surgical oncology* 21 (5), 1616-1623
- 2014 RJ Canter, E Ames, S Mac, SK Grossenbacher, M Chen, J Tellez, **A.M. Monjaze**, WJ Murphy. Tyrosine kinase inhibition with sorafenib but not pazopanib enriches for sarcoma cancer stem cells in diverse models of soft tissue sarcoma. *Cancer Research* 74 (19 Supplement), 1929-1929
- 2014 A. Mirsoian, MN Bouchlaka, G Sckisel, M Chen, CC Pai, E Maverakis, R Spencer, K Fishbein, S Siddiqui, **A Monjaze**, B Martin, S Maudsley, C Hesdorffer, L Ferrucci, DL Longo, BR Blazar, R Wiltrout, DD Taub, WJ Murphy. Adiposity as a Principal Component of Lethal Cytokine Storm Following Cancer Immunotherapy in Aged Mice. *Blood* 124 (21), 460-460
- 2015 N Yuen, C Li, **A Monjaze**, V Khatri, RJ Bold, RJ Canter. The Impact of Radiotherapy on Rates of Surgical Site Infection in Patients with Rectal Cancer: Benchmarks for Comparison. *ANNALS OF SURGICAL ONCOLOGY* 22, S87-S87
- 2015 G Sckisel, A Mirsoian, J Tietze, **A Monjaze**, B Blazar, R Wiltrout, W Murphy. Strong systemic cancer immunostimulatory therapies cause stress-induced acute thymic involution (VAC12P. 1114). *The Journal of Immunology* 194 (1 Supplement), 213.5-213.5
- 2015 ME Daly, K Kelly, A Reddy, GD Sckisel, RN Donahue, WJ Murphy, **AM Monjaze**. Peripheral Blood Immunophenotype Changes Following Thoracic Stereotactic Ablative Radiotherapy *JOURNAL OF THORACIC ONCOLOGY* 10 (9), S441-S442.
- 2015 **AM Monjaze**, M Kent, SK Grossenbacher, W Murphy Blocking indolamine 2, 3 dioxygenase mediated rebound immune suppression improves systemic anti-tumor effects of radio-immunotherapy. *Journal for immunotherapy of cancer* 3 (2), P368
- 2015 R Canter, SK Grossenbacher, JS Park, J Modiano, E Ames, S Mac, **AM Monjaze**, M Kent, W Culp, M Chen, W Murphy. Combination radioimmunotherapy with adoptive

- NK transfer targets cancer stem cells in canine models of bone and soft tissue sarcoma. *Journal for immunotherapy of cancer* 3 (S2), P4
- 2016 T Henderson, M Chen, S Grossenbacher, S Park, C Li, C Chiu, **A Monjaze**, R Bold, W Murphy, R Canter. Genomic Alterations in Cancer Stem Cell Marker CD44 Predict Oncologic Outcome in Soft Tissue Sarcoma. *ANNALS OF SURGICAL ONCOLOGY* 23, S145-S145
- 2016 S Azghadi, D Candas, **AM Monjaze**, M Fan, JS Mayadev, JJ Li. CD47 as a Target for Immune-Radiation Therapy for HER2-Expressing Breast Cancer Cells. *International Journal of Radiation Oncology• Biology• Physics* 96 (2), S147
- 2017 M Daly, J Novak, **A Monjaze**. P2. 05-056 Safety of Stereotactic Body Radiotherapy for Central, Ultracentral, and Paramediastinal Lung Tumors. *Journal of Thoracic Oncology* 12 (1), S1066
- 2017 D Wei, RJ Canter, H Qiu, **AM Monjaze**, M Chen. Radiation therapy related down-regulation of PD-L1 on high-grade poorly differentiated sarcomas justify the combined radio-immunotherapy. *LABORATORY INVESTIGATION* 97, 27A-27A
- 2017 CM Minnar, GD Sckisel, JMT Beerthuijzen, EG Aguilar, A Mirsoian, M Crittenden, BR Blazar, **AM Monjaze**, WJ Murphy. Systemic Stimulatory Cancer Immunotherapy Induces Corticosterone-mediated Thymic Involution. *The Journal of Immunology* 198 (1 Supplement), 120.2-120.2
- 2017 D Candas, L Zhang, C Menaa, M Fan, Y Zhang, L Liu, W Zhou, S Azghadi, C Sweeney, R Shen, T Lin, CX Pan, AT Vaughan, JM Wang, HW Chen, K Lam, LQ Sun, **AM Monjaze**, WJ Murphy, JJ Li. Abstract LB-226: Dual inhibition of CD47 and HER2 to radiosensitize breast cancer cells. *Cancer Research* 77 (13 Supplement), LB-226-LB-226
- 2017 MT Silvestrini, ES Ingham, LM Mahakian, A Kheirrolomoom, Y Liu, BZ Fite, SM Tam, S Tucci, KD Watson, AW Wong, **AM Monjaze**, NE Hubbard, WJ Murphy, AD Borowsky, KW Ferrara. Neoadjuvant immunotherapy improves efficacy of image-guided thermal ablation to generate curative responses in a murine breast cancer model. *Cancer Research* 77 (13 Supplement), 576-576
- 2017 JS Mayadev, CS Li, BA Dyer, **AM Monjaze**, RK Valicenti, ME Daly. Prospective Randomized Control Trial Investigating the Impact of a Physician Communicated Radiation Therapy Plan Review on Breast Cancer Patient-Reported Satisfaction. *International Journal of Radiation Oncology• Biology• Physics* 99 (2), S40
- 2017 HM McGee, ME Daly, JS Mayadev, RC Fragoso, SSD Rao, RK Valicenti, K Kelly, WJ Murphy, **AM Monjaze**, EM Maverakis. Peripheral Blood Immunophenotyping Following Stereotactic Ablative Radiation Therapy. *International Journal of Radiation Oncology• Biology• Physics* 99 (2), S164
- 2018 RJ Canter, E Aguilar, Z Wang, C Le, L Khuat, C Dunai, R Rebhun, A Tarantal, BR Blazar, **A Monjaze**, WJ Murphy. Obesity results in higher PD-1-mediated T-cell suppression but greater T-cell effector functions following blockade. *Journal of Clinical Oncology* 36 (5), 65

- 2018 BA Dyer, D Campos, D Hernandez, C Wright, T Yamamoto, JR Perks, **AM Monjaze**, SSD Rao. Patient-Specific, Tissue-Equivalent Three-Dimensional Printed Bolus Improves Dosimetric Outcomes to Superficial and Irregular Radiation Targets. International Journal of Radiation Oncology• Biology• Physics 102 (3), e490-e491
- 2018 HM McGee, H Anastos, M Galsky, J Sfakianos, ME Daly, **AM Monjaze**, RG Stock, M Buckstein, D Mulholland. Characterization of the Immune Exhaustion Phenotype in Murine Bladder Cancer Following Radiation. International Journal of Radiation Oncology• Biology• Physics 102 (3)S154-S155
- 2018 J Riess, K Kelly, K Schalper, M Shimoda, S Lim, **A Monjaze**, K Danenberg, E Moore, L Beckett, P Mack, E Maverakis, D Gandara. Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI. Journal of Thoracic Oncology 13 (10).
- 2019 S Judge, IR Sturgill, JI Luna, M Chen, JS Park, **AM Monjaze**, MA Darrow, WJ Murphy, RJ Canter. Low-dose Sorafenib Enriches for Cancer Stem Cells and Accelerates Tumor Progression in Sarcomas and Other Solid Tumors. ANNALS OF SURGICAL ONCOLOGY 26, S57-S57.
- 2019 AA Gingrich, SB Bateni, S Thorpe, L Jones, AR Kirane, **AM Monjaze**, MA Darrow, RJ Bold, RL Randall, RJ Canter. Primary Site Surgery is Associated with Improved Survival in Metastatic Soft Tissue Sarcoma of the Extremity. ANNALS OF SURGICAL ONCOLOGY 26, S186-S186.
- 2019 J Chen, J Ji, MT Cho, **A Monjaze**, S Gholami, EJH Kim. Phase I/II trial of BMS-986205 and nivolumab as first-line therapy in hepatocellular carcinoma. Journal of Clinical Oncology 37 (8), TPS57-TPS57.
- 2019 **A Monjaze**, A Giobbie-Hurder, A Lako, AA Tesfaye, A Stoinney, RD Gentzler, S Jabbour, OB Alese, OE Rahma, JM Cleary, E Sharon, D Raben, HJ Mamon, H Streicher, HX Chen, M Ahmed, E Gjini, S Rodig, FS Hodi, JD Schoenfeld. Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiotherapy. Journal of Clinical Oncology 37 (8), 49-49.
- 2019 AA Gingrich, SB Bateni, **AM Monjaze**, SW Thorpe, AR Kirane, RJ Bold, RJ Canter. Extremity soft tissue sarcoma in the elderly: Are we overtreating or undertreating this potentially vulnerable patient population? Journal of surgical oncology 119 (8), 1087-1098.
- 2019 S Azgahdi, D Candas, B Xie, L Zhang, Y Zhang, M Fan, L Liu, C Sweeney, CX Pan, O Ozpiskin, A Vaughan, JM Wang, S Xia, **AM Monjaze**, GE Woloschak, D Grdina, WJ Murphy, LQ Sun, H Chen, K Lam, RR Weichselbaum, JJ Li. Dual Blockade of CD47 and HER2 Re-sensitizes Resistant Breast Cancer Cells to Radiation Therapy. International Journal of Radiation Oncology• Biology• Physics 105 (1), E39.
- 2019 M Daly, **A Monjaze**, A Mirhadi, D Eastham, F Lara, J Riess, E Wiegner, K Kelly. A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 14 (10), S254.

- 2019 S Judge, C Dunai, I Sturgill, K Stoffel, P Chevallier, C Retiere, **A Monjaze**, R Canter, W Murphy. Characterization of tumor infiltrating and post HSCT NK and T cells in human cancer patients. JTC (7).
- 2019 **A Monjaze**, A Giobbie-Hurder, A Lako, M Awad, R Gentzler, C Lee, J Hubbard, J Abbruzzese, S Jabbour, N Uboha, K Stephans, J Johnson, H Park, L Villaruz, K Kao, E Sharon, D Raben, R Mak, H Streicher, H Chen, M Ahmed, S Rodig, FS Hodi, J Schoenfeld. A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L) 1 directed therapy: ETCTN 10021. JTC (7).
- 2019 LT Khuat, CT Le, CC Pai, R Shields-Cutler, S Holtan, A Rashidi, S Parker, D Knights, JI Luna, C Dunai, Z Wang, IR Sturgill, K Stoffel, AA Merleev, E Maverakis, H Raybould, M Chen, RJ Canter, **AM Monjaze**, JLM Ferrara, JE Levine, DL Longo, M Abedi, BR Blazar, WJ Murphy. Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood134 (Supplement_1: 1922).
- 2020 S Judge, I Sturgill, LV Vick, MA Darrow, AM Monjaze, WJ Halabi, S Gholami, WJ Murphy, RJ Canter. Phenotype and Function of Tumor Infiltrating T and NK Cells in Soft Tissue Sarcomas: Prognostic Implications. ANNALS OF SURGICAL ONCOLOGY 27 (SUPPL 1), S139-S139.
- 2020 J Chen, J Huynh, **A Monjaze**, MT Cho, EJH Kim. A pilot study of intratumoral SD-101 (toll-like receptor 9 agonist), nivolumab, and radiotherapy for treatment of chemotherapy-refractory metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology 38 (4_suppl), TPS782-TPS782.
- 2020 SJ Judge, C Dunai, CT Le, LT Khuat, LV Vick, KM Stoffel, AM Monjaze, RJ Canter, WJ Murphy. Differences in NK and Memory CD8 T cell responses to antigen-nonspecific stimulation by interleukin-15. The Journal of Immunology 204 (1 Supplement), 148.17-148.17
- 2020 AA Gingrich, T Reiter, S Judge, D York, M Yanagisawa, I Sturgill, R Brady, K Stoffel, **A Monjaze**, CT Brown, R Rebhun, RJ Canter. Transcriptomic profiles improve characterization natural killer cells and predict response to cytokine therapy in clinical trial for dogs with pulmonary metastases. Cancer Research 80 (16 Supplement), 1339-1339.
- 2020 AA Gingrich, T Reiter, SJ Judge, I Sturgill, **AM Monjaze**, WJ Murphy, C Titus Brown, Robert J Canter. Cross-species gene expression analysis of human, canine and murine natural killer cells suggests convergence of activated dog and human transcriptomic profiles. The Journal of Immunology 204 (1 Supplement), 92.24-92.24
- 2020 K Kelly, ME Daly, A Mirhadi, F Lara, LA Garcia, S Chen, D Eastham, EA Wiegner, JW Riess, KA Schalper, **A Monjaze**. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer. Journal of Clinical Oncology 38 (15_suppl), 9011-9011

- 2020 S Judge, M Darrow, S Thorpe, A Gingrich, E O'Donnell, A Bellini, I Sturgill, L Vick, C Dunai, K Stoffel, Y Lyu, S Chen, M Cho, R Rebhun, **A Monjaze**, W Murphy, R Canter. Tumor infiltrating lymphocytes in soft tissue sarcomas upregulate the exhaustion marker TIGIT and are reinvigorated by IL-15 stimulation and TIGIT blockade. Journal for ImmunoTherapy of Cancer 8 (Suppl 3)
- 2020 A Gingrich, T Reiter, S Judge, D York, M Yanagisawa, I Sturgill, R Brady, K Stoffel, **A Monjaze**, R Rebhun, CT Brown, R Canter. Cross-species immunogenomic analysis identifies pathways of canine natural killer cell response to cytokine therapy, and reveals convergence of activated dog and human. Journal for ImmunoTherapy of Cancer 8 (Suppl 3)
- 2022 SM Cruz, AA Gingrich, AM Razmara, S Judge, **A Monjaze**, S Thorpe, MA Darrow, RJ Canter. Tumor Infiltrating Lymphocytes and Peripheral Blood Neutrophil-to-Lymphocyte Ratios in Soft Tissue Sarcoma Patients are Predictive of Metastasis-Free Survival. ANNALS OF SURGICAL ONCOLOGY 29 (SUPPL 2), 491-491
- 2022 AA Gingrich, C Sholevar, S Judge, SM Cruz, S Thorpe, MA Darrow, **A Monjaze**, J Carr-Ascher, RJ Canter. Intratumoral T Cells with Low TIGIT Expression Are Associated with Improved Disease-free Survival in Soft Tissue Sarcoma. ANNALS OF SURGICAL ONCOLOGY 29 (SUPPL 2), 399-399
- 2022 LM Perry, SM Cruz, MA Darrow, LB Jones, UN Basmaci, N Joshi, ML Settles, BP Durbin-Johnson, **A Monjaze**, J Carr-Ascher, S Thorpe, S Judge, WJ Murphy, J Eisen, RJ Canter. Patients with Soft Tissue Sarcomas Harbor an Intratumoral Microbiome Which is Linked with Immune Infiltrate and Prognosis. ANNALS OF SURGICAL ONCOLOGY 29 (SUPPL 2), 495-495
- 2022 J Huynh, MT Cho, **AM Monjaze**, KW Tam, A Singh, S Naderi, G Fananapazir, R Lamba, J McGahan, TW Loehfelm, S Navarro, SL Stewart, F Lara, A Martinez, LA Garcia, EJ Kim. Phase I/II trial of BMS-986205 and nivolumab as first line therapy in hepatocellular carcinoma. Journal of Clinical Oncology 40 (16_suppl), e16200-e16200
- 2022 L Vick, Z Wang, C Collins, L Khuat, C Dunai, K Stoffel, S Yendamuri, S Mukherjee, S Rosario, R Canter, **A Monjaze**, W Murphy. Sex-linked differences in obesity markedly impact the anti-tumor efficacy of PD-1 blockade. Journal for ImmunoTherapy of Cancer 10 (Suppl 2)
- 2022 M Sheng, C Le, C Dunai, L Khuat, L Vick, K Stoffel, **A Monjaze**, C Collins, R Canter, W Murphy. PD-1 Inhibits Bystander T Cell Activation and Protects from Activation Induced Cell Death. Journal for ImmunoTherapy of Cancer 10 (Suppl 2)
- 2022 ME Daly, M Redman, CB Simone II, **AM Monjaze**, JR Bauman, P Hesketh, J Feliciano, R Kashani, C Steuer, AK Ganti, M Jielling, J Moon, C Hu, JD Bradley, K Kelly. SWOG/NRG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab+ SBRT vs. SBRT Alone in High Risk, Early-Stage NSCLC (NCT# 04214262). International Journal of Radiation Oncology* Biology* Physics 114 (3), e414
- 2023 DJ Yoon, LT Khuat, C Collins, L Vick, G Sckisel, CM Minnar, C Dunai, B Curti, NJ Chao, B Blazar, DL Longo, R Canter, **A Monjaze**, WJ Murphy. Systemic Cancer Immunostimulatory Therapies and Acute Viral Infection Induce Corticosteroid-Mediated

- Thymic Involution and Naïve T cell Output in Mice and Humans. The Journal of Immunology 210 (1_Supplement), 145.21-145.21
- 2023 C Sholevar, SM Cruz, K Iranpur, SJ Judge, A Gingrich, LE Farley, A Razmara, M Lammers, S Thorpe, **AM Monjaze**, WJ Murphy, RJ Canter. Tumor infiltrating natural killer cells in soft tissue sarcoma are predominantly CD56 dim: Implications for outcomes. The Journal of Immunology 210 (1_Supplement), 237.07-237.07
- 2023 LV Vick, LT Khuat, C Le, C Dunai, C Collins, R Canter, **A Monjaze**, WJ Murphy. PD-1 signaling serves a dual role in suppressing T cell activation but also in protecting from activation-induced cell death. The Journal of Immunology 210 (1_Supplement), 226.11-226.11
- 2023 T Cordero, PL Beagen, ME Daly, **AM Monjaze**, X Zhao. 3D Surface Imaging in Reducing Setup Error for Prone Whole Breast Radiotherapy. International Journal of Radiation Oncology, Biology, Physics 117 (2), e172
- 2023 LV Vick, D Yoon, JR Perks, JJ Li, WJ Murphy, **AM Monjaze**. Tumor Resistance to Fractionated Radiotherapy in Obese Mice. International Journal of Radiation Oncology, Biology, Physics 117 (2), S139
- 2023 M Lammers, S Judge, L Farley, K Iranpur, R Nielsen, A Razmara, **A Monjaze**, W Murphy, R Canter. Context dependent effects of TIGIT expression on circulating versus intratumoral NK and CD8 T cells in mouse and human sarcoma models. Journal for ImmunoTherapy of Cancer 11 (Suppl 1)
- 2024 S Veeravelli, M Dall'era, S Gulati, N Mitsiades, R Verma, CP Evans, T Chandrasekar, **AM Monjaze**, PN Lara, M Parikh. A phase 1 study of IO102-IO103 vaccine plus pembrolizumab in patients with BCG-intolerant or unresponsive non-muscle invasive bladder cancer (NMIBC). Journal of Clinical Oncology 42 (4_suppl), TPS716
- 2024 WJ Murphy, L Vick, R Canter, S Rosario, **A Monjaze**. Diverse effects of obesity on cancer immunology and therapy: Both the good and the bad. Cancer Research 84 (7_Supplement), SY38-01